79307-93-0Relevant articles and documents
Preparation method of azelastine hydrochloride
-
, (2021/07/01)
The invention relates to the technical field of synthesis of raw material medicines, and particularly discloses a preparation method of azelastine hydrochloride. The method comprises the following steps: condensing benzoyl hydrazine and 1-methylhexahydroazepine-4-one serving as raw materials, reducing with sodium borohydride, and reacting to obtain a compound 1; preparing a solid intermediate compound 2 from the compound 1 and organic binary weak acid; hydrolyzing the compound 2, and cyclizing with a compound 3 to form a compound 4; and salifying the compound 4 by hydrochloric acid, and separating water by toluene to obtain a compound 5, namely azelastine hydrochloride. The intermediate compound 2 prepared by the invention is a solid, the stability of the intermediate compound 2 is greatly improved compared with that of hydrochloride obtained in other literatures, the intermediate compound 2 is free of hygroscopicity, the purity can reach 99% or above, the quality risk of subsequent bulk drugs can be greatly reduced, and the process production operation space is larger; and the obtained azelastine hydrochloride does not contain water and meets related quality standards, the yield is increased to 80% or above compared with other literatures, and the purity can reach 99% or above.
Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation
-
, (2008/06/13)
The invention relates to azelastine hydrochloride-containing percutaneous preparations which comprises, as base ingredients; hydrocarbon and/or beeswax, and a surfactant.
Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
-
, (2008/06/13)
Pharmaceutical combination, applicable topically, containing a non-sedating antihistamine in combination with an α-adrenergic agonist and optionally conventional physiologically acceptable carriers, diluting agents and auxiliaries substances for the prophylaxis and treatment of allergic and/or vasomotoric rhinitis, conjunctivitis, cold, cold-like and/ or flu symptoms are claimed.
Preparation of pharmaceuticals by hydroformylation. Part III. The synthesis of N-(4-Pyridyl)-3,3-diphenyl-1-aminopropane (Phenpyramine, Milverine)
Marchetti,Sechi,Botteghi,Paganelli
, p. 74 - 76 (2007/10/03)
N-(4-Pyridyl)-3,3-diphenyl-1-aminopropane (1) (Phenpyramine, Milverine), an important amino-pyridine derivative endowed with Muscarinic antagonist activity, is prepared starting from 1,1-diphenylethene using the hydroformylation as key the step in the reaction scheme: the obtained aldehyde was transformed in the desired compound 1 by a three steps reaction sequence; the overall yield was up to 42.8%.